TREM-1 protein test for HER2-negative breast cancer
Part of Cancer, Skin clinical trials.
This study is looking at a protein called TREM-1 in the blood or tumor tissue of women with HER2-negative breast cancer. The goal is to see if TREM-1 levels can predict how well the cancer responds to treatment before surgery, which could help guide more personalized care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be a woman age 18 or older.
- Have a confirmed diagnosis of breast cancer (from a biopsy).
- Your cancer is HER2-negative (meaning it does not have too much HER2 protein).
- You are planning to receive chemotherapy or hormone therapy before surgery (called neoadjuvant therapy).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well a new test can help manage her2-positive early-stage breast cancer. It includes patients who have had treatment before or after surgery with trastuzumab and possibly pertuzumab.
This study uses a radioactive tracer to see how much HER2 protein is on your breast cancer cells. The scan may help doctors understand the type of HER2 you have and choose the best treatment.
This trial studies a more precise way to measure HER2 levels in breast cancer tissue. It may help identify patients whose cancer is HER2-low or HER2-zero, so they can get more targeted treatment.
This trial tests a personalized treatment plan for HER2-positive breast cancer that has spread. It uses a blood test to track cancer DNA and adjust therapy, including treatments that may help prevent cancer from reaching the brain. The goal is to achieve long-term remission.
This study looks at a blood test (DiviTum TKa) to see how well it measures treatment response in people with hormone receptor-positive (HR+) breast cancer that has spread. The test may help doctors know if a treatment is working.
This study looks at how breast cancer cells change during chemotherapy and immunotherapy before surgery. By analyzing tumor samples taken during treatment, doctors hope to find early signs of whether the treatment is working, which could lead to better-personalized care for people with triple negative or high-risk luminal breast cancer.
Hear when a new Breast Cancer Stage I trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.